CREDIT CARDS ACCEPTED | 6% OFF CRYPTO | 3RD-PARTY TESTING (JANOSHIK)
Menu
Cart
Tesamorelin with ipamorelin 5 mg blend lyophilized vial
tesamorelin certificate of analysis
tesamorelin HPLC
Ipamorelin certificate of analysis
Ipamorelin hplc
ipamorelin janoshik third-party test

Tesamorelin + Ipamorelin Blend 5mg / 5mg – 10 Vial Box

$342.00

Cost per vial $: 34.2

Buy tesamorelin + ipamorelin blend 5 mg (one 10-vial box). All orders are shipped wholesale in unbranded packaging. Worldwide 7 – 14 day shipping to the USA, UK, AUS & NZ.

Bulk discounts
Quantity Bulk Discount Price
2 5% $324.90
3-5 7% $318.06
6-10 10% $307.80
SKU: TESIPA5 Categories: ,

Description

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It works by stimulating the pituitary gland to produce and release more growth hormone (GH). Ipamorelin is another peptide that tells the body to produce and release more growth hormone by mimicking the action of the natural peptide ghrelin.

Combining the two can lead to synergistic effects on growth hormone because they work through different mechanisms.

Minimum order quantity: one box (10 vials x 5/5 mg).

Additional information

Purity

≥99.0%
Cost per vial $

34.2
  1. Wang, Ying, and Brian Tomlinson. "Tesamorelin, a human growth hormone releasing factor analogue." Expert Opinion on Investigational Drugs 18.3 (2009): 303-310.
  2. Grunfeld, Carl, Argyris Dritselis, and Peter Kirkpatrick. "Tesamorelin." Nature Reviews Drug Discovery 10.2 (2011): 95-97.
  3. Clemmons, David R., Sam Miller, and Jean-Claude Mamputu. "Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial." PLoS One 12.6 (2017): e0179538.
  4. Falutz, Julian, et al. "Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation." Aids 22.14 (2008): 1719-1728.
  5. Stanley, Takara L., et al. "Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial." The Lancet HIV 6.12 (2019): e821-e830.
  6. Falutz, Julian, et al. "Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data." The Journal of Clinical Endocrinology & Metabolism 95.9 (2010): 4291-4304.
  7. Stanley, Takara L., et al. "Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial." Jama 312.4 (2014): 380-389.
  8. Spooner, Linda M., and Jacqueline L. Olin. "Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy." Annals of Pharmacotherapy 46.2 (2012): 240-247.
  9. Raun, Kirsten, et al. "Ipamorelin, the first selective growth hormone secretagogue." European journal of endocrinology 139.5 (1998): 552-561.
  10. Andersen, N. B., et al. "The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats." Growth Hormone & IGF Research 11.5 (2001): 266-272.
  11. Beck, David E., et al. "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients." International journal of colorectal disease 29 (2014): 1527-1534.
  12. Gobburu, Jogarao VS, et al. "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers." Pharmaceutical research 16 (1999): 1412-1416.

Tesamorelin CoA 2023

Tesamorelin HPLC

Ipamorelin CoA 2024

Ipamorelin HPLC

Related products